Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,632,047 shares, a decrease of 10.2% from the November 15th total of 6,268,579 shares. Currently, 4.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 710,788 shares, the short-interest ratio is presently 7.9 days.
Synthetic Biologics (SYN) opened at $0.53 on Tuesday. Synthetic Biologics has a twelve month low of $0.41 and a twelve month high of $1.05.
Synthetic Biologics (NYSEAMERICAN:SYN) last released its earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by ($0.10).
About Synthetic Biologics
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.